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Abstract Genome targeting has quickly developed as one
of the most promising fields in science. By using pro-
grammable DNA-binding platforms and nucleases, scien-
tists are now able to accurately edit the genome. These
DNA-binding tools have recently also been applied to
engineer the epigenome for gene expression modulation.
Such epigenetic editing constructs have firmly demon-
strated the causal role of epigenetics in instructing gene
expression. Another focus of epigenome engineering is to
understand the order of events of chromatin remodeling in
gene expression regulation. Groundbreaking approaches in
this field are beginning to yield novel insights into the
function of individual chromatin marks in the context of
maintaining cellular phenotype and regulating transient
gene expression changes. This review focuses on recent
advances in the field of epigenetic editing and highlights its
promise for sustained gene expression reprogramming.
Keywords Epigenetics  Gene expression  Chromatin 
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Introduction
Epigenetics is the study of heritable yet reversible changes
in gene expression, which are independent of the under-
lying DNA sequence. Although all cells within an organ-
ism contain the same DNA, there are many different cell
types, making the various tissues and organs, present.
Many genes are constantly activated or repressed leading to
these different phenotypes [1]. This epigenetic gene regu-
lation is mediated by several mechanisms that work toge-
ther in order to determine the cell type-specific patterns of
expression. The organization of DNA and histones into
chromatin is an important aspect in gene regulation,
through which the access of transcription complexes to the
DNA can be regulated [2]. Chromatin is organized in
nucleosomes (protein octamers, generally consisting of two
copies of each core histone H2A, H2B, H3, and H4, where
147 base pairs of DNA is wrapped around) and a linker
histone (H1). Higher-order folding of the nucleosomes can
result in many chromatin states, with the simplest classi-
fication being less condensed, active euchromatin or highly
condensed, silent heterochromatin [3].
Next to maintaining mitotically stable expression pat-
terns, chromatin controls DNA accessibility through, for
instance, post-translational modifications (PTM) of the
histone tails or modification on the DNA such as methy-
lation [4]. These modifications can directly or indirectly
influence chromatin structure by modulating DNA–histone
interactions and form docking sites to facilitate recruitment
of proteins to the chromatin [5]. This form of epigenetic
regulation is important for the maintenance of cell identity
and therefore it is implicated in processes such as prolif-
eration, development, and differentiation [6]. The patterns
of histone PTMs that occur on the histone tails form a so-
called histone code that can be deciphered by other
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proteins. These proteins can alter the structure of higher-
order chromatin and in turn recruit other effector molecules
[7, 8].
For several years, it has been under heavy debate whe-
ther chromatin marks are the cause or mere consequence of
gene expression or repression [9–11]. Most studies
addressing chromatin and RNA expression are based on
statistical associations of various chromatin marks with
expression levels of the genes [12–14]. Such studies firmly
established associations between, for example, H3K4me
and active gene expression, or H3K9me and H3K27me and
gene repression. However, it is worth mentioning that
correlation does not necessarily imply causation. Epige-
netic research has long been hindered by the lack of
experimental methods that would allow the targeted
manipulation of chromatin marks in living cells. Most of
the studies have used mutational approaches and pharma-
cological inhibition to alter epigenetic marks, but this has
global and non-chromatin effects [15, 16]. Nevertheless,
using these techniques scientists have been able to provide
further support that loss of chromatin modifiers causes
strong phenotypes, which are often interpreted as a con-
sequence of transcriptional deregulation, although the cel-
lular effects might very well be established through
changes in non-chromatin targets [17].
An elegant approach to actually rewrite epigenetic
modifications at a known locus was the targeting of epi-
genetic effector domains to reporter genes. Early research
made use of synthetic protein–DNA-binding approaches
(e.g., Gal4, LacR), or fused existing human DNA-binding
domains to (parts of) epigenetic enzymes (e.g., MLL, NF-
kB). Currently, it is feasible to target epigenetic effector
domains to any given genomic locus (referred to as ‘‘epi-
genetic editing’’ [18•], making it experimentally possible to
modify individual chromatin marks at a defined locus and
chromatin context [19, 20].
The goal of such epigenetic editing is to rewrite an
epigenetic mark at any locus at will, and eventually mod-
ulate the expression of endogenous genes. In order to
rewrite a gene’s epigenetic signature a (catalytic domain of
a) writer or an eraser can be targeted to the given locus by
fusing it to a programmable gene-specific DNA-binding
domain (DBD) [21–29]. Induced epigenetic changes can be
determined by, e.g., chromatin immuno-precipitation
(ChIP) or bisulfite sequencing and the actual effect of
targeting epigenetic enzymes on gene expression can be
assessed by measuring gene expression levels of genes that
are in close proximity of the DBD recognition site. In this
review, we summarize recent epigenetic editing reports
using different DNA-binding platforms and several acti-
vators, repressors, or epigenetic enzymes targeted to
endogenous loci.
Gene Targeting Platforms
In recent years, the molecular biology field has developed
three protein systems to design domains with predeter-
mined DNA sequence-binding specificity. C2H2 zinc fin-
ger proteins (ZFPs) were the first example of modular and
predictable DNA recognition proteins and a few research
groups worldwide, including ours [30–33], exploited this
first generation system to demonstrate its power to modu-
late expression of any given gene of interest. These early
studies were exploiting non-catalytic domains to modulate
gene expression including, e.g., a viral transcriptional
activator (VP16 and its tetramer VP64) [34, 35] or the
mammalian repressor KRAB [30, 36]. More recently, a
more straightforward programmable recognition domain
platform was introduced: the Transcription-Activator-Like
Effector (TALE) arrays [19]. Both platforms, however,
require the fusion of the effector domain to every newly
engineered DNA-binding domain, which is a laborious,
expensive, and greatly hampered progress. The introduc-
tion of the Clustered Regulatory Interspaced Short Palin-
dromic Repeats (CRISPR) sequences with CRISPR-
Associated Protein (Cas) or CRISPR/Cas9 systems has
made epigenetic editing available to the wider research
community as it consists of two simple modular parts: a
sgRNA (which is easy to design and cheap) and its to be
recruited counterpart, the protein dCas (allowing a one-
time fusion to an epigenetic editor for all possible targets)
[37]. Indeed, recent findings clearly indicate the promise of
epigenetic editing to reprogram gene expression patterns,
and are discussed below.
ZFPs
ZFPs are among the most common types of DNA-binding
motifs found in eukaryotes and are present in many natural
transcription factors. They can be engineered to recognize
almost any DNA sequence [38]. ZFPs are made of modular
zinc finger domains in which each finger consists of ca 30
amino acids containing one a-helix and two b-sheets that
are coordinated by a zinc ion, generally with two residues
of cysteine and two residues of histidine. Three amino
acids on the surface of the a-helix typically contact three
base pairs in the major groove of DNA [39]. By linking six
ZF domains together, a 6-ZFP can be engineered to rec-
ognize 18 base pairs of DNA, which is mathematically
unique in the genome [40]. This way, ZFPs can be used to
target DNA sequence in the genome. An individual finger
domain recognizing a 3 base pair segment of choice is
selected from lists of artificially constructed fingers, such
as Barbas modules for 50-GNN-30, 50-ANN-30, 50-CNN-30,
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and a partial 50-TNN-30 [41]. For many years, engineering
ZFPs was the only approach available to create custom
site-specific DNA-binding proteins. Nevertheless, they are
expensive, labor intensive to create, and not highly specific.
On the other hand, they constitute the smallest of the three
currently available platforms. One of the most important
rules to designing DNA-binding platforms has been the use
of DNAse hypersensitive sites, which mark regions of open
chromatin. Interestingly, ZFPs due to their size are able to
bind highly chromatinized regions in the genome, in con-
trast to other platforms [42•]. Additionally, they are pre-
sumably less immunogenic due to their similarity to
mammalian transcription factors. Currently, engineered
ZFPs are available commercially from Sigma–Aldrich (St.
Louis, MO, USA), and are the only domains, which have
been explored in clinical trials, for over ten years now
(Sangamo Biosciences, Richmond, CA, USA).
TALEs
TALEs are derived from the bacterium species Xan-
thomonas. In host plants, they affect gene expression by
binding to promoters of disease resistance-related genes
and regulate their expression to facilitate bacterial colo-
nization and survival. TALEs contain 13–28 highly con-
served tandem repeats of 33 or 34 amino acid segments;
these repeats mostly differ from each other at amino acid
positions 12 and 13 [19, 43]. Unique combinations of
amino acids at the positions 12 and 13 bind to specific
corresponding nucleotides, allowing for gene targeting (for
example, NI to A, HD to C, NG to T, and NN to G or A).
Like ZFPs, modular TALE repeats are linked together to
recognize contiguous DNA sequences. Although the single
base recognition of TALE to the DNA allows greater
design flexibility than triplet-confined ZFPs, the cloning of
repeat TALE arrays presents a technical challenge due to
extensive identical repeat sequences. Moreover, their big
sizes and immunogenicity likely will hamper their uses in
clinical applications. Likewise, DNA methylation has been
shown to hamper the binding of TALEs, restricting their
accessibility at heterochromatin regions [44].
CRISPR
The discovery of the CRISPR-Cas system has been one of
the most important advances of the century in molecular
biology research. CRISPR-Cas originally was identified to
act as an immune system in bacteria, but is now largely
exploited as a gene-targeting platform because of the ease
of the approach. There are at least three different CRISPR
classes under development, with type II CRISPR/Cas9 of
Streptococcus pyogenes being the simplest design, com-
posed of a single endonuclease protein Cas9. CRISPR-
Cas9 main function is to detect pathogenic DNA and shred
it. Recognition of pathogenic DNA is achieved by incor-
porating the short host DNA segment in the Cas locus of
the bacteria. This DNA is transcribed into a so-called
single guide RNAs (sgRNAs) that recognize the host target
genomic sequence of approximately 20 bps upstream of a
50-NGG-30 protospacer adjacent motif (PAM). The
requirement of a PAM sequence slightly limits the target-
ing freedom of CRISPR/Cas9, occasionally making the use
of ZFPs and TALEs more advantageous in cases where no
50-NGG-30 sequence is present. Upon binding, the Cas9
nuclease can cleave double-stranded DNA with its RuvC-
like nuclease domain and HNH nuclease domain. Keeping
the nuclease activity intact thus allows for gene editing by
inducing double-stranded DNA breaks and relying on
homologous recombination (HR) or non-homologous end
joining (NHEJ) for cellular DNA repair. The nuclease
domains of Cas9 can be enzymatically inactivated through
mutations in the RuvC and HNH domain, thereby creating
the nuclease-null deactivated Cas9 (dCas9), e.g., gene
expression manipulation purposes. CRISPR offers similar
high levels of efficiency to TALEs, and its design and
implementation is simpler than that of ZFPs and TALES.
However, several concerns have also been raised regarding
the specificity of the CRISPR system. Mismatches between
the DNA target sequence and RNA molecule are tolerated,
increasing the possibility for off-target effects. Addition-
ally, the size and immunogenicity of the Cas9 protein make
the clinical application of the system a likely hurdle. These
limitations require further exploration. However, this sys-
tem has opened several opportunities to study a plethora of
applications in biology, such as gene expression modula-
tion. Interestingly, the first ex vivo clinical trial using
CRISPR for genome editing has been approved recently
[45].
Artificial Transcription Factors
The fusion of transcriptional effector domains to designed
DNA-binding domains can induce transcriptional activa-
tion or repression when targeted to endogenous genes. The
ZFPs were the first to be linked to the transcriptional
activator VP16 to create an artificial transcription factor
[38, 46]. VP16 is an activation domain from the herpes
simplex virus that recruits the RNA polymerase II tran-
scriptional machinery [47]. Later, a tetramer of VP16
domains (VP64) was created and has been linked to several
DNA-binding platforms to activate coding and non-coding
genes by targeting the promoters and regulatory elements
in the genome. However, VP64 does not directly modify
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chromatin and has been shown to have a transient effect on
gene expression [42•]. Nevertheless, it recruits several
factors linked to increased chromatin accessibility and the
deposition of active histone marks, such as acetylation of
the lysine 27 residue of histone subunit 3 (H3K27ac)
[48, 49]. Another activator exploited for targeted gene
activation is the p65 subunit of the human NF-jB complex,
which has been coupled to ZFPs [50], TALEs [51, 52], and
dCas9 [53]. Gene induction by these activators can be
achieved by targeting both up- and downstream of tran-
scription start sites (TSSs) in promoter regions. However,
the activation of gene expression using these proteins has
not been very efficient in all cases, depending on the region
targeted, and for this reason recruitment of multiple DNA-
binding domains to a locus is often required to achieve a
robust transcriptional response, especially in the case of
dCas9 system.
In order to overcome low efficiency of activation, a new
generation of activators have been developed that allow
robust gene overexpression in comparison to the original
domains. These new activators work by amplifying the
recruitment of multiple effectors to a single dCas9-gRNA
complex. For example, the SUperNova Tagging (SunTag)
system, which recruits multiple VP64 activators to dCas9
in trans, results in stronger activation with a single gRNA
[54]. Alternatively, repurposing the gRNA as a scaffold to
recruit activators via MS2-targeting has been proven
effective: The authors fused several RNA hairpins from the
male-specific bacteriophage-2 (MS2) to the 30end of a
sgRNA and fused the MS2 coat protein (MCP), which
binds the MS2 hairpin, to VP64, resulting in efficient
activation [55]. Similarly, the synergistic activation medi-
ator (SAM) system uses two MS2 hairpins in the sgRNA
and fuses MCP to the activators p65 and HSF-1 (Heat
Shock Factor 1, responsible for transcribing genes in
response to temperature) [56]. This system is used in
combination with dCas9–VP64 and showed a significant
improvement compared to the other systems. Lastly, the
VPR system using three separate activators (VP64, p65,
and Rta) has been shown to achieve high levels of
expression [53].
Transcriptional repression has also been accomplished
by using targeted gene silencing with engineered DNA-
binding domains fused to repressors. Targeting of a DNA-
binding domain without any effector domain to promoter
regions or regions downstream of the transcription start site
can silence gene expression by steric hindrance of tran-
scription factors and RNA polymerase [46, 57]. However,
gene repression by this method alone generally is not
sufficient for robust silencing. Transcriptional repressors,
which by themselves possess no catalytic activity but can
recruit epigenetic modifiers, are more potent for silencing.
The most commonly used silencing domain is the Kru¨ppel-
associated box (KRAB), which is one of the most potent
natural repressors in the genome and used by half of all
mammalian zinc finger transcription factors. Localizing
KRAB to DNA can initiate heterochromatin formation by
recruitment of complexes that may include the histone
methyltransferase SETDB1 and the histone deacetylase
NuRD complex [58–60]. In addition to silencing of pro-
moters, KRAB has been shown to repress gene expression
when targeted to distal and proximal gene regulatory ele-
ments like enhancers [30, 61–63].
Given the success of gene expression modulation by the
use of artificial transcription factors, the possibility of using
epigenetic modifications to manipulate the cellular
machinery in a more sustained manner and to recruit
writers or erasers to study the role of specific marks in
different chromatin contexts was raised [18, 64]. Since
epigenetic marks are inherited by daughter cells, the
reprogramming might even be stable and maintained
through cell divisions [6, 65]. The possibility to easily
reverse epigenetic modifications in a targeted manner has
opened new and exciting avenues for fundamental bio-
logical research. Indeed, the dynamic and reversible nature
of the epigenetic modifications offers the possibility to
reprogram any gene at will (Fig. 1). And that was how the
epigenome editing field was born. Below we discuss the
most used epigenetic effector domains in epigenetic editing
(Table 1).
Epigenetic Repression
The very first epigenetic modifier linked to a DNA-binding
domain to establish epigenome editing was published in
2002 when an engineered ZF, designed to target the VEGF-
A gene, fused to the histone methyltransferases G9a or
SUV39H1 was able to show that H3K9 methylation is
causative in VEGF-A gene repression [64]. It took a while
before this study was followed by ZF-targeting the HER2/
neu gene in cancer [66] and even in vivo by targeting the
murine Fosb gene [67•]. Similarly, authors have fused a
TALE, targeting the E-Cadherin gene, and dCas9, in
combination with sgRNAs to target VEGF-A, to the SET
domain of the histone methyltransferase G9a and demon-
strated that this approach is effective in repressing genes,
as seen with ZFPs [68, 69]. In the meantime, Zinc Fingers
were also exploited in the first DNA methylation targeting
studies by fusion to the catalytic domains of DNA
methyltransferases Dnmt3a or including a fusion between
Dnmt3a and Dnmt3L, which catalyze the de novo methy-
lation of DNA. In these studies, the authors showed that
targeted DNA methylation at gene promoters, of genes
such as VEGF-A [70], SOX2 and Maspin [71, 72•], and
EpCAM [73], gene repression was achieved effectively.
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Similar results have been obtained by targeting the
CDKN2A gene using a TALE fused to DNMT3A [74] as
well as dCas9 using sgRNAs to target the CDKN2A, ARF,
Cdkn1a, IL6ST, and BACH2 genes, demonstrating the
potency of epigenome editing [75, 76].
Currently, several engineered TALE domains as well as
dCas9 proteins have also been fused to various histone
modifiers. For example, for the catalytic domain of the
LSD1 histone demethylase, authors were able to efficiently
remove enhancer-associated chromatin modifications from
Fig. 1 Epigenetic editing tools
available. a Zinc finger proteins
can recognize double-stranded
DNA, fusion of 6 ZFPs can
recognize an 18 bps sequence,
and fused to a DNA
methyltransferase like DNMT3a
can add methylation to
cytosine’s. b TALEs can
recognize each module a single-
base pair, fusion of several can
recognize a locus, and fused to
an oxidizing enzyme like TET1
can promote DNA
demethylation. c CRISPR-
dCas9 can bind to a sequence
complementary to the sgRNA
that is loaded with, and fused to
a histone acetyltransferase like
p300 can activate gene
expression










Repression G9a Methyltransferase H3K9me2 VEGF-A, Her2INeu, Fosb, E-Cadherin, Neruog, Grm2
Suv39h1 Methyltransferase H3K9me3 VEGF-A, Her2INeu, Neruog, Grm2
DNMT3 (A,
A/L)
Methyltransferase DNA methylation VEGF-A, SOX2, Maspin, EpCAM, CDKN2A, ARF,
Cdkn1a,IL6ST, BACH2
LSD1 Demethylase H3K4me2 Gene enhancers
SIRT6, SIRT3 Deacetylase H3K9ac Neruog, Grm2
KYP Methylase H3K9me1 Neruog, Grm2
TgSET8 Methylase H3K20me Neruog, Grm2
NUE Methylase H3K27me3 Neruog, Grm2
HDAC8 Deacetylase H4K8ac Neruog, Grm2
RPD3 Deacetylase H4K8ac Neruoq, Grm2
Sir2a Deacetylase H4Kac Neruoq, Grm2
Sin3a Deacetylase H3K9ac Neruog, Grm2
Activation TET1 Deoxygenase DNA demethylation ICAM-1, RHOXF2, BRCA1, RANKL, MAGEB2, MMP2
TET2 Deoxygenase DNA demethylation ICAM-1, EpCAM
TET3 Deoxygenase DNA demethylation ICAM-1
TDG Glycosylase DNA demethylation Nos2
p300 Acetylase H3K27ac IL1RN, MYOD1, OCT4, HBE, HBG,ICAM-1
PRDM9 Methyltransferase H3K4me3 EpCAM,ICAM-1, RASSF1a, PLOD2
Dot1L Methyltransferase H3K79me EpCAM, PLOD2
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targeted regions, without affecting control regions [61, 77].
Additionally, they found that removal of enhancer chro-
matin marks by these fusion proteins causes downregula-
tion of proximal genes. Furthermore, using a set of 32 and
24 histone modifiers fused to TALEs targeting the Neurog2
and Grm2 genes, respectively, in combination with opto-
genetics for light induction, it was possible to assess the
role of histone marks on the regulation of gene expression
[78].
Epigenetic Activation
In contrast to epigenetic repression, activation of epige-
netically silenced genes has been more challenging. So far,
only few active epigenetic marks have been addressed. The
most common way to achieve gene re-expression has been
done by using active DNA demethylation. ZFPs fused to the
catalytic domain of TET1, TET2, and TET3 have been used
to activate ICAM1 gene expression, in a hypermethylated
heterochromatic context, being TET2 the most efficient
[79]. Alternatively, ZFPs have been used to enhance gene
expression by fusion with the DNA demethylase thymidine
DNA glycosylase (TDG) [80]. In other studies, researchers
have fused the DNA demethylase TET1 to engineered
TALEs targeting the RHOXF2 gene, which led to the
identification of the specific CpGs playing a role in gene
expression [81]. Also, the CRISPR-dCas9 has also been
fused to TET1 catalytic domain and was used to target the
BRCA1 promoter, showing active DNA demethylation and
gene upregulation [82]. Recently, a dCas9 system was
further modified, by inserting two copies of bacteriophage
MS2 RNA elements into the conventional sgRNAs, facili-
tating the tethering of the TET1 catalytic domain, in fusion
with dCas9 or MS2 coat proteins, to target the RANKL,
MAGEB2, or MMP2 genes, and significantly upregulate
gene expression, which was in close correlation to DNA
demethylation of CpGs in their promoters [83]. Addition-
ally, dCas9, TALEs, and ZFPs have been fused to the cat-
alytic core of the p300 histone acetyltransferase to deposit
H3K27ac and activate gene expression from promoters and
distal enhancers [84•]. Recently, we have shown that
induction of H3K4me3 as well as H3K79me, both marks
are specific for active promoters, on silenced genes is
enough to drive gene re-expression [42•].
Next Stage of Epigenetic Editing: Sustained
Epigenetic Reprogramming
Now that causality of epigenetic marks with respect to gene
expression has been firmly proven, the next most funda-
mental question in epigenetic editing research is whether
the newly introduced chromatin marks are stable and
whether they are maintained over cell divisions. Indeed, the
success of future clinical applications relies on longlasting
epigenetic reprogramming. Only a few of the epigenetic
editing studies have showed the mechanism of inheritance
and stability of the epigenetic marks. The first studies
concerned DNA methylation and H3K9 methylation for
gene repression. On one hand, successful deposition of
DNA methylation at the promoter of the VEGF-A gene
caused effective silencing but, interestingly, the methyla-
tion and gene silencing were lost upon cessation of
expression of the ZFP-fusion [85•]. On the other hand,
another study showed that the induction of DNA methy-
lation on the MASPIN tumor suppressor and SOX2 onco-
gene resulted in stable silencing and was maintained
through cell divisions [72•]. The differences in the results
of these studies might be related to the different technical
approaches (transient adenovirus infection vs. lentiviral
insertion of inducible systems) and/or by the duration of
the expression of the fusion proteins. Alternatively, these
differential effects could be explained by the different
chromatin contexts.
In an elegant paper, Bintu and colleagues used an arti-
ficial system to compare four repressive chromatin regu-
lators that result in distinct chromatin modifications [86]:
The EED protein of Polycomb repressive complex 2, which
catalyzes H3K27 methylation; the KRAB domain that
indirectly promotes H3K9 methylation; the DNMT3B that
catalyzes DNA methylation; and the histone deacetylase 4
(HDAC4) enzyme. By transiently recruiting each protein
for different periods of time they demonstrate that different
types of repressed chromatins are generally associated with
distinct time scales of repression. While DNA methylation
shows a clear longstanding repression, histone deacetyla-
tion is less stable and has a fast recovery. Epigenetic
editing studies are now required to confirm the general
application of these findings for the various endogenous
chromatin contexts.
While sustained gene repression by epigenetic enzymes
seems conceptually more feasible, sustained gene activa-
tion is indeed poorly understood. In this sense, we have
recently shown the different requirements to achieve
longstanding gene re-expression that is maintained over
time, depending on the chromatin microenvironment [42•].
While reactivation is achieved on hypomethylated pro-
moters, hypermethylated promoters are less prone to sus-
tained re-expression. Additionally, the requirement of
histone post-translational modification crosstalk is an
important event during reprogramming. H3K4me3 requires
the presence of H3K79me in order to be stabilized and
successfully maintained. Based on these, and other findings
[87], it might turn out that the chromatin microenvironment
greatly affects the outcome of epigenetic reprogramming.
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Clinical Applications and Future Perspectives
Aberrant gene expression due to epigenetic misregulation
has been associated with several diseases, either as a
symptom or even as a cause. The potency of epigenetic
editing as a therapy is based on the reversible nature of
epigenetic (mis)regulation [88]. In contrast to genetic
mutations, epigenetic mutations thus allow for the possi-
bility of reverting the abnormal patterns at a molecular
level. Furthermore, site-specific epigenetic editing provides
the opportunity to study the contributions of gene regula-
tion to disease. The possible applications of epigenome
editing can go as broad as from targeted reprogramming of
cells via induced pluripotent stem cells to specialized cell
types for clinical applications, to induction of genes
involved in diseases with allelic imbalanced expression
[89], and anticancer therapy.
Most of the focus so far has been placed on developing
inhibitors of epigenetic enzymes, which act genome-wide
and thus might suffer from side effects. The technology to
activate endogenous genes by epigenetic rewriting of their
own promoters allows physiological levels of expression,
which likely resembles the natural conditions in normal
cells better and is more specific than the small molecules
inhibitors. The in vivo effectivity of the epigenetic editing
approach has, for instance, been shown by the activation of
glial cell line-derived neurotrophic factor (GDNF) using
ZFPs in rat models, which resulted in protection against
neural damage associated with Parkinson’s disease [90]. In
this respect, activation of genes which compensate exis-
tence of mutated genes will allow the actual cure or at least
the mitigation of the symptoms of diseases such as sickle
cell anemia and b-thalassemia. For example, targeted
activation of the developmentally silenced fetal c-globin
using ZFPs was achieved in mammalian cells, and could be
used to counteract the loss of b-globin [91, 92]. In a
pioneering study, researchers were able to activate multiple
isoforms of VEGF-A with engineered ZFPs resulting in
stimulation of functional angiogenesis in vivo, which was
not achieved by exogenous overexpression of just one
isoform [93]. Gene re-expression can also be used as a
targeted therapy in cancer, as upregulation of silenced
tumor suppressor genes is enough to induce cell death and
inhibit cell migration, as proven by endogenous activation
of several genes in cancer using ZFPs [33, 94, 95]. Addi-
tionally, engineered ZFP repressors have been designed to
silence oncogenes and have been effective at slowing the
growth of cancer cells not only in in vitro, but also in
mouse models [30, 63, 72].
Although most of the mentioned studies have been
done using transient transcriptional activators or
repressors as effector domains, eventually, some of the
findings are expected to be further optimized into thera-
peutic use by adopting epigenetic editing for such in vivo
situations. There is already evidence that epigenetic
editing therapy is feasible based on in vivo studies where
targeting of the murine Fosb gene in the brain of living
mice successfully controlled the drug response in regions
of the brain harboring the reward system. In another
study, targeting of SOX2 promoter with ZFPs fused to
DNA methyltransferases significantly delayed the
tumorigenic phenotype of cancer cells in vivo and,
importantly, the repression was stably maintained. Addi-
tional attention is currently given to aspects that require
research in depth such as immunogenicity, cytotoxicity,
off-target effects, and mode of delivery, in order to take
these tools further into the clinic.
Conclusions
Gene expression reprogramming can be achieved by tar-
geted epigenetic editing of regulatory regions, and several
DNA-binding platforms have been investigated for target-
ing various catalytically active epigenetic enzyme domains
to multiple genes. The development of engineered DNA-
binding domains has opened the possibility to address
questions that were impossible to answer few years ago.
Nevertheless, several aspects have to be addressed to fully
exploit the approach for clinical applications, as delivery
and sustainability are still an issue. Unraveling mechanisms
for sustained gene re-expression necessitates the ongoing
research into reinforcing epigenetic mechanisms depending
on the chromatin microenvironment. Epigenetic editing
can be used as a powerful research tool to study epigenetic
molecular mechanisms as well as a biomedical tool toward
a cure for what currently is incurable.
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